John F Cabelka Ii, MD Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 2000 Pepperell Pkwy, Radiation Oncology, Opelika, AL 36801 Phone: 706-604-0622 |
News Archive
Roche announced today that the cobasĀ® TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A virus (HAV) simultaneously in one assay in human plasma.
In an effort to educate and inform consumers, Water Pik, Inc., a global leader in personal healthcare products, today announced the launch of its new online community on Waterpik.com. Powered by Lithium Technologies, the online destination supports Water Pik's entire portfolio of oral health, shower head and sinus health products and brings the company's experts, consumers and industry experts together in one digital space.
Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.
Edesia LLC, a non-profit producer of life-saving Ready-to-Use Foods (RUFs), is the recipient of a $2 million multi-year grant from the U.S. Agency for International Development.
Researchers from the Universities of Warwick, Edinburgh, Dundee and the Czech Republic's Institute of Biophysics have discovered a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use "light activation" to kill cancer cells in much more targeted way than similar treatments.
› Verified 8 days ago